euro adhoc: Marseille-Kliniken AG
Financial Figures/Balance Sheet
- Turnover
increases to EUR 58.0 million in Q1 2008/2009
- Net group income EUR 2.1 billion according to IFRS
- Rehabilitation following positive development in Care
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement.
3-month report
10.11.2008
Berlin, 10 November 2008. Marseille-Kliniken AG (Prime Standard, ISIN DE 0007783003, MKA) was able to further increase its operating turnover by 5.8 % to EUR 58.0 m in the first quarter of the current financial year (previous year: EUR 54.9 m). Net group income after minority interest declined from EUR 7.0 m to EUR 2.1 m as planned due to one-off effects (EUR 4.9 million) in the previous year´s quarter. Per share this amounts to earnings of EUR 0.17 compared to EUR 0.57 in the previous year. EBIT/IFRS reached EUR 3.5 m after EUR 4.3 m in the previous year. EBITDAR/IFRS amounted to EUR 17.0 m after the previous figure of EUR 15.7 m. Equity was recorded at EUR 85.6 m compared to EUR 82.4 m in the previous year. The equity ratio was therefore increased to 37.4 % (previous year: 28.5 %).
Declining earnings can be mainly attributed to the fact that the impacts of the corporation tax reform 2008 were factored into the previous year´s results, which at that point resulted in a tax gain of EUR 4.9 m. There were none of these or similar one-off effects in the period under review.
Adjusted earnings according to DVFA/SG (IFRS) from the previous year´s period amounted to EUR 4.8 m, and were almost reached in the first quarter of the current financial year at EUR 4.7 m. This amounts to EUR 0.39 per share (previous year: EUR 0.39). Adjusted EBITDAR increased from EUR 16.8 m in the previous year to EUR 17.6 m, while adjusted EBIT fell from EUR 6.6 m to EUR 5.8 m. Already high occupancy levels at group level improved even further and with a capacity of 9,100 beds (previous year: 8,801 beds) reached a value of 92.6 % compared to 92.3 % in the previous year. Adjustments mainly relate to dormancy costs of currently unused facilities in the Rehabilitation segment as well as start-up losses in eight care institutions with 741 beds (9.5 % of capacity).
Capacity in Care increased from 7,518 to 7,794 beds as of the reporting date. Turnover in the segment was up from EUR 43.0 m to EUR 44.9 m compared to the previous year. As expected earnings according to DVFA/SG (IFRS) reached EUR 3.7 m compared to EUR 4.8 m in the previous year. The causes mainly relate to higher energy costs and general price increases for foodstuffs. Occupancy levels were down slightly on the previous year at 93.1 % compared to 93.8 %.
The segment Rehabilitation is extremely successful. Capacity increased to now 1,306 beds (previous year: 1,283 beds) as a result of using 23 additional beds for Rehabilitation at the care clinic Bad Schönborn. Segment turnover increased from EUR 11.9 m to EUR 13.1 m. Earnings according to DVFA/SG (IFRS) increased considerably from breaking even in the previous year to EUR 1.0 million. Restructuring measures implemented are therefore showing sustained success. This is also reflected in occupancy levels, which were up from 86.9 % in the previous year to 92.6 %.
Given that developments are on plan in the period under review, Marseille-Kliniken AG has a positive outlook for the future. A continuing increase in occupancy levels, especially in expansion institutions, will have a positive impact on turnover and earnings. In addition to that, optimisation measures are going to result in cost saving potentials being tapped in the current financial year. For the full financial year 2008/2009 the company is confirming its growth forecast, which is projecting an increase in turnover of 6.5 % and an EBIT return of at least 7 %.
For more detailed information, please visit the website www.marseille-kliniken.de to read the quarterly report.
End of ad hoc release
end of announcement euro adhoc
Further inquiry note:
Marseille-Kliniken AG
Axel Hölzer
CEO
Alte Jakobstraße 79/80
10709 Berlin
Germany
Tel.: +49 30 / 246 32-400
Fax: +49 30 / 246 32-401
www.marseille-kliniken.de
Hillermann Consulting
Christian Hillermann
Investor Relations for Marseille-Kliniken AG
Poststraße 14/16
Germany
Tel.: +49 40 / 320 279 10
Fax: +49 40 / 320 279 114
www.hillermann-consulting.de
Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: CDAX, Classic All Share, Prime All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hamburg / regulated dealing